Insights
Recon takes an analytical look behind select developments in healthcare
Keep up with Recon Strategy Insights
Get an email each time we publish a new article
Search
- By David Kaufmann, Marc Herant, Jason Brauner
Summary
After challenging conditions in 2022, deal-driven biotech spending appears to have picked up in 2023. To quantify this trend we have systematically reviewed deals announced during this period …
- By Marc Herant
A Chinese study uncovers a new use for an old drug
Bleeding in the small intestine is often due to vascular malformations and is difficult to diagnose and manage because 1) the area is hard to reach w…
- By Sarah Dolman
PDF here
Summary
The idea of a single blood-test to detect many cancers is attractive, but is it practical? Can an MCED enhance, or even replace, current screening tests?
This paper delves into these …
- By Marc Herant
How the US taxpayer saved 25M+ people
A short piece celebrating the 20th anniversary of PEPFAR, a program that few outside of the field of Global Health are aware of. The world is not always nasty and…
- By Marc Herant
Preparing for the next pandemic: don’t waste the value of waste
During the Covid-19 pandemic, I got in the habit of checking weekly the Boston sewage report, as a reliable, unbiased way of monitoring …
- By Nikhil Bhojwani
What does Socrates have to do with AI? And what's the Spooky Mountain and why we need to conquer it to get to an AI enabled future?
https://www.youtube.com/watch?v=5V10R6lcIl4…
- By Lilian Zhang, Jason Brauner, and Marc Herant
PDF: Trends and strategy in oncology development
Summary
We review a sample of oncology programs from the past decade and arrive at the following key findings:
The use of expansion cohorts in first-i…
- By Marc Herant
Hypertension?!
Antihypertensive drugs are so 80s and 90s (well, except for pulmonary hypertension) to the point that I cannot recall when I last read research in the NEJM about a new blood pressure dr…
- By Jacob Wiesenthal and Sarah Dolman
View the PDF here.
The supply chain of pharmaceuticals consumed in the US has become reliant on foreign sources of drug products and intermediates over the last two decades. Growth of generics and bio…